Bardy Diagnostics, provider of ambulatory cardiac monitoring technologies and custom data solutions, has announced it has raised $35.5 million (US) in Series B funding, which it will use to further accelerate growth of its P-wave focused cardiac monitoring platform through expansion of the sales force and monitoring services, and to support advanced development programs, including augmented intelligence and visualisation technologies.
Gust H. Bardy, founder and chief executive officer of Bardy Diagnostics, said in a press release: “The calibre of our new investors, in addition to our exceptional existing syndicate of financiers, underscores the exciting opportunity before us. With these funds, we will grow our business by refining and expanding our primary goal of revealing to patients, and their physicians, the full complexity and meaning of their cardiac rhythm.”
The company says its Carnation Ambulatory Monitor (CAM) is the only P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device. It is designed to be worn in the centre of the chest, directly over the heart for optimum electrocardiogram (ECG) signal collection, and is suitable for use by adults and children weighing more than 10kg (22lbs).